Annual | 12/2023FY | 12/2024FY |
---|---|---|
Total Revenue | $9.43 B | $9.42 B |
Net Income | $3.05 B | $1.16 B |
Quarterly | 9/30/2023 | 12/31/2023 |
Total Assets | $28.19 B | $26.84 B |
Total Liabilities | $12.05 B | $11.35 B |
Operating Margin | 7.81% | 18.49% |
Biogen, Inc.
225 Binney Street |
|
Industry | Pharmaceuticals: Major |
---|---|
Sector | Health Technology |
Employees | 7,570 |
Mr. Christopher A. Viehbacher | Mr. Christopher A. Viehbacher | Mr. Michael R. McDonnell | |||||||||||||||||||||
President, Chief Executive Officer & Director | President, Chief Executive Officer & Director | Chief Financial Officer & Executive Vice President | |||||||||||||||||||||
Mr. Michael E. Dambach | Ms. Robin C. Kramer | Dr. Jane Grogan | Ms. Nicole Murphy | Ms. Nicole Murphy | Dr. Eric K. Rowinsky | Dr. Eric K. Rowinsky | Dr. Stephen A. Sherwin | Dr. Stephen A. Sherwin | Mr. Monish Patolawala | Mr. Monish Patolawala | Mr. Christopher A. Viehbacher | Ms. Susan Langer | Mr. William A. Hawkins | Mr. Jesus B. Mantas | Mr. Jesus B. Mantas | Dr. Maria C. Freire | Dr. Maria C. Freire | Ms. Caroline D. Dorsa | Ms. Caroline D. Dorsa | Mr. William A. Hawkins | Ms. Susan Langer | Mr. Wendell C. Taylor | |
Treasurer & Vice President | Chief Accounting Officer & Senior Vice President | Executive Vice President & Head-Research | Head-Pharmaceutical Operations & Technology | Head-Pharmaceutical Operations & Technology | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | President, Chief Executive Officer & Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Independent Director | Chairman | Chairman | Independent Director | Independent Director | Secretary & Chief Counsel |
Company Name | Price | EPS (FY) | Annual Dividend | Book Value (FY) | Cash Flow (FY) |
---|---|---|---|---|---|
Biogen, Inc. | $211.17 | 8.05 | 0.00 | 104.48 | 16.06 |